Just - Evotec Biologics
401 Terry Avenue North
About Just - Evotec Biologics
Just - Evotec Biologics, is a unique platform company that integrates the design, engineering, development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus is to create access and value for a global market through scientific and technological innovation. Learn more at www.just.bio.
36 articles about Just - Evotec Biologics
This week's money flowed into various therapeutic areas like cancer and inflammatory disorders, while government and philanthropic grants fund the fight against infectious diseases.
Just – Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
Evotec SE announced that the U.S. Department of Defense has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 49.9 m for the rapid development of monoclonal antibody -based drug product prototypes targeting plague.
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.
Other non-operating result of € (89.8) m (H1 2021: € 106.1 m) explained by the non-cash fair value adjustments of the equity investment in publicly listed Exscientia plc.
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
Evotec SE and Alpine Immune Sciences, Inc. announced that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for the treatment of systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.
Evotec SE will announce its financial results for the first half-year 2022 on Thursday, 11 August 2022.
In a presentation titled "Reaching the goal with higher speed and confidence", CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE's current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG.
Evotec and Sernova partnered to develop an implantable induced pluripotent stem cell (iPSC)-based beta cell replacement therapy that can be used to treat both type 1 and 2 diabetes patients.
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
May 3, 2022 09:00 UTC Tubulis announced the successful completion of a €60 million Series B financing led by Andera Partners with participation from new investors Evotec and Fund+.
Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.
Just Biotherapeutics and Teva Enter an Agreement for the Design and Development of a High Productivity (HP) Biomanufacturing Process
Just Biotherapeutics, Inc. (Just), an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process.
The deal will grow Evotec's business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics and infectious diseases.
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio"), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
ATUM today announced a patent licensing agreement giving Just Biotherapeutics access to the company’s Leap-In cell line development tools.
Just Biotherapeutics Secures $14 Million Series A2 Funding To Build Laboratory, Pilot Plant And GMP Capabilities